

MaNaMa Clinical Genetics

Genome diagnosis

Annelies Dheedene


Sofie Symoens

12 October 2022

Cytogenomic technologies for acquired and constitutional disorders


- Karyotyping
- FISH
- Microarray and shallow whole genome sequencing
- QF-PCR
- NIPT

prebanding cytogenetics




numerical aberrations

high-resolution banding




structural aberrations
(3 to 5 Mb)

CGH




structural aberrations
(2 to 10 Mb)


array CGH



submicroscopic imbalances
(50 to 500 kb)




banding techniques




structural aberrations
(5 to 10 Mb)

FISH



interstitial and (sub)telomeric
imbalances

M-FISH and SKY



complex rearrangements and
supernumerary marker chromosomes

next-generation sequencing


```

>Pair 1, End A
TGTGATCACCCGCCAAATCCATAAACCCGACCGTG
AGCGATGATAGATGACAATGGACCAAAGACGGCCTA
TGGAAATGGATTACGTTTACGACGGATTAGCC
>Pair 1, End B
GTCAGGACGGTACGATGCCAAATGGCCCTAATCGG
TAAGCTTGACGTAACGGTTACCCGATTTAGTCAAT
GCAAATGCAAGGTCCTCCAGTGACCAAGT
>Pair 2, End A
AATGGACCAAATGACACAACGATGAATACCGGATTA
CAGTAGCTGACACATGGAAGTGCACGTAAGTACCCG
ACGTGCACCGTTACGGATTCCGTACTTAACC
...


```

structural variation (>1 kb) and
nucleotide changes

Karyotyping: lymphocytes



karyotyping




PHA
phytohemagglutinine




culture medium



methotrexate +
thymidine
colchicine + hypotonia
fixative



Giemsa staining



Karyotyping

Constitutional

- Blood
- Fibroblasts
- Amniocytes
- CVS
- EBV celline
- (miscarriage)

Acquired

- Bone marrow
- (maligne) blood

prophase



pro-metaphase



metaphase




800 bands




400 bands

G-bands per haploid karyotype




Constitutional blood – short term culture


46,X,i(Y)(p10)



Constitutional blood



Bone marrow



Prenatal amniocytes

Karyotyping

Resolution is dependent on tissue type and culture conditions

Interpretation by skilled personnel

Many manual laboratory steps

General Guidelines and Quality Assurance for Cytogenetics



**A common European framework for quality assessment for constitutional,
acquired and molecular cytogenetic investigations.**


E.C.A. Permanent Working Group for Cytogenetics and Society

Table 5



| | |
|--|---------|
| Amniotic fluid and long term CVS cultures | 17 days |
| Lymphocytes cultures | 28 days |
| Bone marrows and solid tumour cultures | 21 days |
| Solid tissue culture | 28 days |
| Short term CVS cultures (directs) | 7 days |
| Urgent* lymphocyte, cord blood cultures | 7 days |
| Urgent* bone marrows cultures (diagnostic samples) | 7 days |
| Prenatal aneuploidy FISH screening/QF-PCR | 4 days |

ISCN: examples of abnormal karyotypes


- 47,XY,+21
- 45,XX,der(13;21)(q10;q10)
- 46,XY,der(13;21)(q10;q10),+21
- 45,X
- 46,XY,t(6;9)(q24;p23)
- 46,XY,der(6)t(6;9)(q24;p23)dmata
- 46,XY,del(6)(q24q31)
- 46,XY,inv(7)(p14q25)
- 46,XY,inv(17)(q12q22)
- 47,XXY,del(22)(q11.2)
- 46,XX,del(9)(ptelp23)




Fluorescent in-situ hybridization (FISH)




chr 22



Indication: implantation failure





L1801919 (V)




chr10 = green; chr 14 = red

FISH: chr10 = green; chr9 = red



46,XX,ins(9;10)(p22;q11.2q21.2),t(10;14)(q?;q32.3)



Filter Criteria

| | |
|--------------------------------|-----------|
| BED SV OverlapPrecision(Kbp): | 12 |
| BED CNV OverlapPrecision(Kbp): | 500 |
| SV MaskingFilter: | nonmasked |
| CopyNumberType: | all |
| CopyNumberConfidence: | 0.99 |
| CopyNumberMin Size (bp): | 500000 |
| Self MoleculeCount: | 0 |
| % in Control: | 0 |
| % in Control for Enzyme: | 0 |
| SV ChimericScore: | all |
| Found in Self Molecules: | all |
| OverlapGenes: | all |


| SV Filter | Confidence | Min Size (bp) |
|-----------------------|------------|---------------|
| ● Insertion | -1 | |
| ● Deletion | -1 | |
| ● Inversion | -1 | |
| ● Duplication | -1 | |
| ● Intra-Translocation | -1 | |
| ● Inter-Translocation | -1 | |

| BED File | SV | CNV | Action |
|------------------------|----|-----|--------|
| hg38cnvmasks | | | |
| AddBED | | | |



Samples

Reference: hg38_DLE1_0kb_0lab




| 18.22565_denovo_assembly_sv | Count |
|-----------------------------|-------|
| ● Insertion | 2 |
| ● Deletion | 6 |
| ● Inversion | 1 |
| ● Duplication | 0 |
| ● Intra-Translocation | 5 |
| ● Inter-Translocation | 6 |
| ● CNV Gain Segment | 0 |
| ● CNV Loss Segment | 0 |




FISH Philadelphia chromosome
Dual Fusion Translocation Probe






BCR/ABL1 transcripts




QF-PCR




- Fast, multiplex PCR
- Aneuploidy detection for chromosome 13, 18, 21, X and Y
- Maternal contamination
- (Low) mosaicism not detectable
- Structural rearrangements not detectable
- Exercise: diagnosis?
 - Tip: marker D13Sxxx = marker from chr 13, D18Sxxx = marker from chr 18 etc.




Array Comparative Genomic Hybridization (aCGH)



arr[GRCh37] 22q11.21(18915001_21465000)x1



chr 22





Contents lists available at [ScienceDirect](#)

European Journal of Medical Genetics

journal homepage: <http://www.elsevier.com/locate/ejmg>



Review

Implementation of genomic arrays in prenatal diagnosis: The Belgian approach to meet the challenges



Olivier Vanakker^a, Catheline Vilain^d, Katrien Janssens^b, Nathalie Van der Aa^b,
Guillaume Smits^d, Claude Bandelier^h, Bettina Blaumeiser^b, Saskia Bulk^g,
Jean-Hubert Caberg^g, Anne De Leener^d, Marjan De Rademaeker^c, Thomy de Ravel^f,
Julie Desir^e, Anne Destree^e, Annelies Dheedene^a, Stéphane Gaillez^g, Bernard Grisart^e,
Ann-Cécile Hellin^g, Sandra Janssens^a, Kathelijn Keymolen^c, Björn Menten^a,
Bruno Pichon^d, Marie Ravoet^h, Nicole Revencu^h, Sonia Rombout^e, Catherine Staessens^c,
Ann Van Den Bogaert^c, Kris Van Den Bogaert^f, Joris R. Vermeesch^f, Frank Kooy^b,
Yves Sznajder^h, Koen Devriendt^{f,*}

^aCenter for Medical Genetics, Universiteit Gent, Belgium

^bCenter for Medical Genetics, Universiteit Antwerpen, Belgium

^cCenter for Medical Genetics, Vrije Universiteit Brussel, Belgium

^dCenter for Medical Genetics, Université Libre de Bruxelles, Belgium

^eCenter for Medical Genetics, IPG, Charleroi Gosselies, Belgium

^fCenter for Medical Genetics, Katholieke Universiteit Leuven, Belgium

^gCenter for Medical Genetics, Université de Liège, Belgium

^hCenter for Medical Genetics, Université Catholique de Louvain, Belgium

To report



| chr | start in Mb (hg19) | stop in Mb (hg19) | size in kb | CNV | gene | phenotype | morph. anomaly | return? | OMIM | update May 2017 |
|-----|--------------------|-------------------|------------|---|--------------------|--|--|-----------|--------|--|
| 1 | 146,57 | 147,39 | 820 | distal 1q21.1 dup | <i>GJA5 (CX40)</i> | ID, DD, ASD, schizophrenia | macrocephaly, CHD | YES | 612475 | YES |
| 1 | 146,57 | 147,39 | 820 | distal 1q21.1 del | <i>GJA5 (CX40)</i> | ID, DD, ASD, SZ, facial dysmorphism | microcephaly, CHD, renal and urinary tract anomalies | YES | 612474 | YES |
| 1 | 171,81 | 172,38(?) | 57 | 1q24.3 del | <i>DNM3</i> | ID | IUGR, microcephaly, brachydactyly | YES | | |
| 15 | 31,13 | 32,48 | 1350 | 15q13.3 del | <i>CHRNA7</i> | DD, ID, ASD, epilepsy, SZ | microcephaly, CHD | YES | 612001 | YES |
| 15 | 99,36 | 102,52 | 3160 | 15q26 del | <i>IGF1R</i> | MR | IUGR | YES | | YES |
| 16 | 28,74 | 28,96 | 220 | 16p11.2 distal del | <i>SH2B1</i> | obesity, DD, ID, SZ | none | YES | 613444 | YES |
| 16 | 29,59 | 30,19 | 600 | 16p11.2 proximal dup | <i>TBX6</i> | ASD, ID, DD, SZ, anorexia | microcephaly | NO YES | 614671 | moved to YES since actionable; penetrance del and dup comparable |
| 16 | 29,59 | 30,19 | 600 | 16p11.2 proximal del | <i>TBX6</i> | ID, DD, ASD, obesity, SZ, speech delay | macrocephaly, vertebra | YES | 611913 | YES |
| 17 | 34,82 | 36,21 | 1390 | 17q12 deletion syndrome RCAD (renal cysts & diabetes) | <i>TCF2</i> | facial dysmorphism, genital abnormalities, ID, DD, ASD, MODY | renal anomalies | YES | 614527 | YES |
| 22 | 19,02 | 20,29 | 1270 | 22q11.2 dup | <i>TBX1</i> | ASD, ID, DD, dysmorphic features | microcephaly, CHD | YES | 608363 | YES |
| 1 | 144,97 | 146,61 | 1640 | 1q21.1 dup | <i>HFE2</i> | DD, ASD | CHD | NO | | NO |
| 2 | 50 | 51,11 | 1110 | 2p16.3 del | <i>NRXN1</i> | ID, ASD, SZ, DD, dysmorphic features | none | NO | 614332 | NO |
| 2 | 110,87 | 110,98 | 110 | 2q13 dup | <i>NPHP1</i> | ASD, ID | none | NO | | NO |
| 3 | 197,2 | 198,84 | 1600 | 3q29 dup | | MR, DD | none | NO | | NO |
| 13 | 20,81 | 21,01 | 1200 | 13q12 dup | <i>CRYL1</i> | ? | ? | NO | | NO |
| 15 | 22,8 | 23,09 | 290 | 15q11.2 dup | <i>NIPA1</i> | DD, motor delay, speech delay, ASD | none | NO | | NO (likely benign) |
| 15 | 22,8 | 23,09 | 290 | 15q11.2 del | <i>NIPA1</i> | ID, DD, epilepsy | CHD | NO | 615656 | NO (likely benign) |
| 15 | 31,13 | 32,48 | 1350 | 15q13.3 dup | <i>CHRNA7</i> | ADHD, ID, DD, ASD | none | NO | | NO (likely benign) |
| 16 | 14,98 | 16,48 | 1500 | 16p13.11 dup | <i>MYH11</i> | ID, ASD, SZ, ADHD | aorta dilatation | NO | | NO |
| 16 | 14,98 | 16,48 | 1500 | 16p13.11 del | <i>MYH11</i> | ID, DD, ASD, epilepsy | microcephaly | NO | | NO |
| 16 | 21,94 | 22,46 | 520 | 16p12.2 dup | <i>EEF2K, CDR2</i> | ? | ? | NO | | NO (likely benign) |
| 16 | 21,94 | 22,46 | 520 | 16p12.2 del | <i>EEF2K, CDR2</i> | DD, speech dealy | cranofacial and skeletal abnormalities, CHD | NO | 136570 | NO |

Not to report


Single Nucleotide Polymorphism array (SNParray)

SNP genotyping:

- UPD analysis
- homozygosity mapping



SHALLOW WHOLE GENOME SEQUENCING (0,1X - 10X COVERAGE)






Reference genome build



Mapped sample reads

↓ Split in bins (defined by 'bin size')





Reference genome build



Mapped sample reads

Split in bins (defined by 'bin size')




Count



Normalize: \log_2 , median centering, **mappability (*)**, **gc-content (*)**, **blacklist (*)**


(*) depended on reference



duplication


deletion

The cytogenomics toolbox: an example




° 2018
Developmental delay
Language delay

° 2020
Developmental delay
Overgrowth








[137490] 2021-Jun-09 : D2109592.cbs Tax ID: 9606, Build: GRCh38




sseq[GRCh38] 2p25.3(15001_3315000)x1

sseq[GRCh38] 11q25(132195001_135075000)x3




► FISH:


#2 + #11




2ptel + 11qtel



→ 46,XY/XX.ish der(2)t(2;11)(p25.3;q25)



Non-invasive prenatal testing (NIPT)



1st trimester screening



+

maternal age



75 – 85% sensitivity

5% false positives

NIPT

Table 1. Meta-analysis of diagnostic accuracy of cell-free fetal DNA–based non-invasive prenatal test demonstrated by sensitivity and specificity ratio of common tests³⁷.

| Test | Sensitivity | Specificity |
|------------|----------------------------|----------------------------|
| Fetal sex | 0.989 (95% CI 0.980–0.994) | 0.996 (95% CI 0.989–0.998) |
| Rhesus D | 0.993 (95% CI 0.982–0.997) | 0.984 (95% CI 0.964–0.993) |
| Trisomy 21 | 0.994 (95% CI 0.983–0.998) | 0.999 (95% CI 0.999–1.000) |
| Trisomy 18 | 0.977 (95% CI 0.952–0.989) | 0.999 (95% CI 0.998–1.000) |
| Trisomy 13 | 0.906 (95% CI 0.823–0.958) | 1.00 (95% CI 0.999–1.000) |
| Monosomy X | 0.929 (95% CI 0.741–0.984) | 0.999 (95% CI 0.995–0.999) |


CI, confidence interval.



ARTICLE

Outcome of publicly funded nationwide first-tier noninvasive prenatal screening

Kris Van Den Bogaert¹, Lore Lannoo², Nathalie Brison¹, Vincent Gatinois¹, Machteld Baetens³, Bettina Blaumeiser^{4,5}, François Boemer⁶, Laura Boulard⁷, Vincent Bours⁶, Anne De Leener⁸, Marjan De Rademaeker⁵, Julie Désir^{7,9}, Annelies Dheedene³, Armelle Duquenne⁸, Nathalie Fieremans¹⁰, Annelies Fieuw¹⁰, Jean-Stéphane Gatot⁶, Bernard Grisart⁹, Katrien Janssens⁴, Sandra Janssens³, Damien Lederer⁹, Axel Marichal⁹, Björn Menten³, Colombine Meunier⁹, Leonor Palmeira⁶, Bruno Pichon⁷, Eva Sammels¹⁰, Guillaume Smits⁷, Yves Sznajer⁸, Elise Vantroys¹⁰, Koenraad Devriendt¹ and Joris Robert Vermeesch¹✉




Percentage of pregnancies with a fetal or maternal imbalance from first-tier genome-wide NIPT.

[General](#)[Nipt](#)[Info](#)

| # | Date | Name | Fetal Gender | Statistics |
|----------|------------|------------|--------------|--|
| [119758] | 04-12-2019 | CFD1905750 | male | Qscore: 0.55 FFY: 9.11% FFX: 8.78% PREFACE: 8.16% |



Z-scores






[119758] 2019-Dec-04: CFD1905750:cbs, nipt Tax ID: 9606, Build: GRCh38

NIPT chr 18 in detail





Amniocentesis (15w GA) chr 18 in detail NT=3,6mm





maternal duplication as reason for false positive



Z13 = 5.41 → trisomy 13

FF = 12.3%



Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples


P. BENN¹ , F. MALVESTITI², B. GRIMI², F. MAGGI², G. SIMONI² and F. R. GRATI²

Table 4 Observed rates of uniparental disomy (UPD) identified in amniotic fluid, following detection of trisomy in chorionic villus sample

| <i>Imprinted chromosome</i> | <i>Investigated cases (n)</i> | <i>Cases with UPD (n)</i> | <i>UPD rate (% (95% CI))</i> |
|-----------------------------|-------------------------------|---------------------------|------------------------------|
| Trisomy 6 | 3 | 0 | 0 (0–56) |
| Trisomy 7 | 93 | 0 | 0 (0–4) |
| Trisomy 11 | 6 | 0 | 0 (0–39) |
| Trisomy 14 | 15 | 5* | 33 (15–58) |
| Trisomy 15 | 32 | 3† | 9 (3–24) |
| Trisomy 20 | 34 | 0 | 0 (0–10) |
| Total | 183 | 8 | 4.4 (2.2–8.4) |

*Three cases with rare autosomal trisomies (RAT) in cytotrophoblasts and two cases with RAT in mesenchyme. †Two cases with RAT in cytotrophoblasts and one case with RAT in mesenchyme.

“incidental” findings in the mother

Brief Report

September 2015


Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing

Frédéric Amant, MD, PhD¹; Magali Verheecke, MD¹; Iwona Wlodarska, PhD²; Luc Dehaspe, PhD²; Paul Brady, PhD²; Nathalie Brison, PhD²; Kris Van Den Bogaert, PhD²; Daan Dierickx, MD, PhD³; Vincent Vandecaveye, MD, PhD⁴; Thomas Tousseyn, MD, PhD⁵; Philippe Moerman, MD, PhD⁵; [Adriaan Vanderstichele, MD²](#); Ignace Vergote, MD, PhD²; Patrick Neven, MD, PhD²; Patrick Berteloot, MD⁶; Katrien Putseys, MD⁷; Lode Danneels, MD⁸; Peter Vandenberghe, MD, PhD^{2,3}; Eric Legius, MD, PhD²; Joris Robert Vermeesch, PhD²

» [Author Affiliations](#)


JAMA Oncol. 2015;1(6):814-819. doi:10.1001/jamaoncol.2015.1883

NIPT: suspicion maternal malignancy



[93864] 2018-Feb-02 : CFD1800651:cbs, coverage, nipt, WiseCondor Tax ID: 9606, Build: GRCh37

Molecular karyotype:
Resection polyp



→ Liquid biopsy

